Please assess the completion status of the following clinical trial:

Trial Title: BAY94-9027 PK Study Comparing to Another Long Acting Product

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males, age 18 to 65 years.~* Subjects with Severe Hemophilia A with a documented plasma FVIII level of \< 1%~* ≥ 150 exposure days with FVIII concentrate(s) as supported by medical records~Exclusion Criteria:~* Evidence of current or past inhibitor antibody:~* History of any congenital or acquired coagulation disorders other than hemophilia A.~* Platelet count \<75,000/mm\*3.~* Abnormal renal function (serum creatinine \>2 x the upper limit of the normal range).~* Active liver disease verified by medical history or persistently elevated alanine aminotransferase or aspartate aminotransferase \>5 x the upper limit of the normal range or severe liver disease as evidenced by, but not limited to any of the following: International Normalized Ratio \>1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BAY94-9027 and Elocta (Type: EXPERIMENTAL): Subjects received two treatments: 60 IU/kg BAY94-9027 in the first period, followed by 60 IU/kg Elocta in the second period, with a washout period before each treatment
- Elocta and BAY94-9027 (Type: EXPERIMENTAL): Subjects received two treatments: 60 IU/kg Elocta in the first period, followed by 60 IU/kg BAY94-9027 in the second period, with a washout period before each treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).